The Warsaw office of Wolf Theiss has advised the European Investment Bank on a EUR 10 million financing to Scope Fluidics S.A., a Polish medical technology company that designs diagnostic systems. CMS advised Scope Fluidics on the deal.
According to Wolf Theiss, “Scope Fluidics S.A. develops innovative products for medical diagnostics for global health challenges. The firm uses microfluidic technologies for the rapid characterization of antibiotic resistance of bacteria and the detection of pathogens, including COVID-19. Their current technologies include PCR|ONE, which targets healthcare-associated infections and infection control, and BacterOMIC, which is the first of its kind to offer full and actionable information for precision antibiotic therapies. It is expected that the use of such methods will improve the standard of care and the effectiveness of the fight against the current pandemic. The financing for Scope Fluidics comes from a joint European Commission and EIB initiative, the Infectious Diseases Finance Facility, backed by Horizon 2020, the EU Research and Innovation program 2014-2020.”
Wolf Theiss’s team was led by Partners Przemek Kozdoj and Jacek Michalski and included Senior Associate Jakub Pietrasik.
CMS's team was led by Partners Marcin Bejm and Jakub Wieczorek.
